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https://doi.org/10.1002/psc.3232The chalcogen elements oxygen, sulfur, and selenium are essential constituents of
side chain functions of natural amino acids. Conversely, no structural and biological
function has been discovered so far for the heavier and more metallic tellurium ele-
ment. In the methionine series, only the sulfur‐containing methionine is a
proteinogenic amino acid, while selenomethionine and telluromethionine are natural
amino acids that are incorporated into proteins most probably because of the toler-
ance of the methionyl‐tRNA synthetase; so far, methoxinine the oxygen analogue
has not been discovered in natural compounds. Similarly, the chalcogen analogues
of tryptophan and phenylalanine in which the benzene ring has been replaced by
the largely isosteric thiophene, selenophene, and more recently, even tellurophene
are fully synthetic mimics that are incorporated with more or less efficiency into pro-
teins via the related tryptophanyl‐ and phenylalanyl‐tRNA synthetases, respectively.
In the serine/cysteine series, also selenocysteine is a proteinogenic amino acid that
is inserted into proteins by a special translation mechanism, while the tellurocysteine
is again most probably incorporated into proteins by the tolerance of the cysteinyl‐
tRNA synthetase. For research purposes, all of these natural and synthetic chalcogen
amino acids have been extensively applied in peptide and protein research to exploit
their different physicochemical properties for modulating structural and functional
properties in synthetic peptides and rDNA expressed proteins as discussed in the fol-
lowing review.
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In early days of X‐ray crystallography of proteins, one of the main dif-
ficulties was the trial and error soaking procedure for the production
of heavy atom derivatives. It was with the fast and efficient advances
in rDNA technology that using methionine‐auxotrophic Escherichia coli
strains quantitative biosynthetic replacement of methionine by
selenomethionine was used by Hendrickson et al1 to generate atomic
mutants of proteins as a new approach to solve the phase problem in
protein crystallography with the multiwavelength anomalous disper-
sion method.2 This new procedure led to increasing interest in chalco-
gen analogues of amino acids in the methionine and serine/cysteine
series as reviewed in previous literature.3,4 These analogues are
shown in Figure 1 and differ in their physicochemical properties such
as electronegativity, atom volume, and carbon‐metal bond length
depending upon the chalcogen atoms in their side chains.
Additional fully synthetic chalcogen amino acids have been synthe-
sized as isosteric tryptophan (1‐4)5,6 and phenylalanine (5‐8)7-9 ana-
logues, respectively, and were used for in vivo protein synthesis of
chalcogen analogues of proteins for X‐ray analysis and other purposes
(Figure 2).FIGURE 2 Isosteric synthetic chalcogen analogues of tryptophan and phe2 | CHALCOGEN ANALOGUES OF
METHIONINE
In the methionine series, only methionine is a proteinogenic amino
acid, whereas selenomethionine and telluromethionine are natural
amino acids that are inserted into natural proteins because of the tol-
erance of the methionyl‐tRNA synthetase.10-122.1 | Selenomethionine and telluromethionine
protein variants for X‐ray crystallography
Intensive optimization of the expression conditions in Escherichia coli
was required for quantitative replacement of methionine in proteins
with the related chalcogen analogues to produce the highly isomor-
phous protein variants. Moreover, it was noticed that the proteins
have to be biosynthesized in the folded form since oxidation of the
selenium and even more of the tellurium occurs in the unfolded states
as exists in inclusion bodies.3,13-16 The chalcogen protein analogues
are isomorphous and can be considered as atomic mutants of the
native methionine proteins. Therefore, no significant changes in the
overall shape, steric complementarity, and occupation volume are gen-FIGURE 1 Chalcogen amino acids
discovered in natural compounds except
methoxinine
nylalanine
FIGURE 3 Crystallographic mapping of selenomethionine and telluromethionine residues in the spatial structure of recombinant human annexin
V by the difference electron density maps (Fo‐Fc) for (A) Met259→ Sem259 (contouring level 3.0 σ) and for (B) Met273→ Tem273 (contouring
level 5.0 σ) replacement16
FIGURE 4 Spatial structure of rhPrPc‐[125‐231] (PDB accession no.
1QM0). Except for Met‐205/Met‐206, all other methionine residues
of this protein are surface exposed. In the bioexpressed Mox‐hrPrPc‐
[125‐231] protein, all nine Met residues were replaced by
methoxinine19
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tron difference maps (Figure 3), but the protein folds show generally
sufficient plasticity to accommodate such minor differences even in
the case of tellurium. On the other hand, the telluro‐analogues provide
directly heavy atom derivatives for the classical multiple isomorphous
replacement method, but the production is more difficult. Conversely,
the seleno‐mutants in most cases are not suitable for this method and
are more appropriate for multiwavelength anomalous dispersion
experiments that require, however, synchrotron radiation with precise
beam wavelength control.
2.2 | Methoxinine as methionine‐oxide mimic
This additional chalcogen analogue of methionine with sulfur replaced
by oxygen differs from methionine particularly because of its strong
hydrophilicity compared with methionine, selenomethionine, and
telluromethionine. With this hydrophilic property, it resembles the
methionine‐oxide. Because of this particular property, it was reason-
able to expect that a related prion protein (hrPrP‐[125‐231]) Mox‐
analogue could be useful for analysis of the proposed but still not
clearly documented hypothetical role of Met oxidation as the main
cause of the prion protein conversion to its scrapie form.17,18 Indeed
particularly Met‐205 and Met‐206 oxidation was suggested to be
responsible for the conformational transition of the α‐helix into β‐
sheet and thus for the aggregation and the neurotoxic amyloid forma-
tion (see Figure 4).20 The in vitro aggregation propensity of the
Mox‐hrPrPc‐[125‐231] analogue was found to be significantly
increased compared with that of the native Met‐protein (Figure 5).19
Even the content of α‐helix as derived from the circular dichroism
(CD) spectrum was visibly decreased with concomitant shift to β‐
sheet. With the large number of methionine residues in the
PrP‐[125‐231] protein, it is difficult to confirm that the oxidation of
a few selected methionine residues initiates the conformational transi-
tion. However, this is not only supported by the results obtained with
the Mox‐rhPrPc‐[125‐231] analogue but also by experimental results
obtained with model peptide of Dado and Gellman22 where asignificant conformational shift from α‐helix to β‐sheet could be
observed by replacing the hydrophobic norleucine residues as methio-
nine analogues with the hydrophilic Mox residues.193 | SULFUR‐ AND SELENIUM‐CONTAINING
TRYPTOPHAN ANALOGUES
The β‐(thienopyrrolyl)‐ and β‐(selenolopyrrolyl)‐L‐alanine (compounds
1‐4 in Figure 2) are synthetic mutually isosteric amino acids that mimic
tryptophan with the benzene ring in the indole moiety replaced by
thiophene and selenophene, respectively. These tryptophan mimics
are prepared enzymatically from the [3,2‐b]‐ and [2,3‐b]‐fused
FIGURE 5 Comparative in vitro aggregation
properties of Met‐hrPrPc‐[125‐231] and Mox‐
hrPrPc‐[125‐231] (A) as determined by
confocal single molecule analysis with
fluorescence cross‐correlation
spectroscopy21; CD spectra of Met‐hrPrPc‐
[125‐231] and Mox‐hrPrPc‐[125‐231] (B)
recorded in 10mM 2‐(N‐morpholino)
ethanesulfonic acid buffer at pH 6.0 and in the
presence of 0.2% SDS to prevent aggregation
4 of 15 MORODER AND MUSIOLselenolopyrroles and thienopyrroles23 with the Salmonella typhimurium
tryptophan synthase5,6 as shown in Figure 6.
Tryptophan represents a suitable target for its replacement in pro-
teins with synthetic isosteric analogues of near‐equal volumes and
approximately identical electron densities. Moreover, Trp is known
to occur rather rarely in proteins as it represents only about 1% of
all residues of globular proteins.24 Correspondingly, chalcogen‐
containing Trp analogues provide quasi‐site–specific probes for study-
ing protein structure, dynamics, and function via their incorporation
into recombinant proteins in response to the Trp UGG codons by fer-
mentation inTrp‐auxotrophic E coli host strains and applying the selec-
tive pressure incorporation (SPI) method.25-27 Under routine
bioexpression protocols, an almost quantitative incorporation of both
β‐(thienopyrrolyl)alanines in annexin V that contains only one Trp res-
idue and in the pseudo‐wild–type barstar mutant C40A/C82A/P27A/
W38F (b*) with two Trp residues was achieved.28 The barstar mutant
is obtained in inclusion bodies and is refolded into the native form dur-
ing the purification procedure. Both the annexin V and barstar Trp
analogues proved to be stable, and despite exposure to air and light
for days, a degradation of the thienopyrrolyl moieties was not
observed. Both proteins were found to exhibit reduced thermal stabil-
ity but full retention of the biological activities. Although these protein
mutants retain the secondary structure of the native proteins, they
were found to differ significantly in optical and thermodynamic
properties.
In view of these positive results, the β‐selenolo[3,2‐b]pyrrolyl‐L‐
alanine was incorporated into human annexin V and barstar mutantFIGURE 6 Enzymatic synthesis of β‐(thienopyrrolyl)‐ (1,2) and β‐(selenolopyrrolyl)‐L‐alanine (3,4)5,6b* C40A/C82A/P27A as model proteins in Trp‐auxotrophic E coli
using the SPI method. The seleno‐proteins were obtained in yields
comparable with those of the wild‐type proteins and the
β‐(thienopyrrolyl)‐L‐alanine mutants.29 Both selenium‐containing
mutants were found to exhibit crystallographic isomorphism with the
parent proteins. Although the selenium‐containing Trp analogue
replaces in annexin V the fully exposed Trp‐187 and in the barstar
mutant the two Trp residues 44 and 38 partially or fully exposed to
solvent, their exceptional stability can be regarded as a considerable
advantage over selenomethionine in replacement experiments for
crystallographic phasing. The most probable explanation for this
observed high stability is a resonance stabilization of the Se atoms in
aromatic rings where the chalcogen atom is less prone to oxidation
than in dialkylselenides, such as selenomethionine. Moreover, in cases
where Sem is less suitable for diffraction analysis because of the
atomic mobility factors, the use of the selenotryptophan analogue
could be an alternative.4 | SULFUR‐ , SELENIUM‐ , AND
TELLURIUM‐CONTAINING PHENYLALANINE
ANALOGUES
On the basis of early reports of du Vigneaud et al30 on the incorpora-
tion of β‐2‐thienylalanine (5 in Figure 2) into proteins, already in the
early 1960s, it could be demonstrated that this phenylalanine ana-
logue is inserted into the enzyme β‐galactosidase in a Phe‐requiring
MORODER AND MUSIOL 5 of 15auxotroph of E coli.31 This result confirms the largely isosteric charac-
ter of the thiophene ring with the benzene ring although of less aro-
matic character, having a resonance energy of 25 kcal/mol as
compared with 36 kcal/mol for benzene. The catalytic properties of
the enzyme with about 95% of the phenylalanine residues replaced
by the analogue were retained; however, the enzyme was found to
be significantly less stable to heat, urea, and enzymatic degradation.
Later in the 1970s, the β‐2‐thienylalanine has also been incorporated
synthetically in various peptide hormones such as vasopressin and
bradykinin leading to full retention or even increased bioactivities.32,33
Conversely, the β‐2‐ and β‐3‐selenienyl‐L‐alanines (6 and 8 in
Figure 2) have been synthesized as potential diagnostic agents for dis-
orders in the pancreas8 but so far did not find any application in
replacement experiments for crystallographic phasing. However, very
recently, a detailed study on the stability of various organotellurium
compounds revealed for 2‐alkyl‐tellurophenes high stability to aerobic
oxidation in both organic and aqueous solutions and a limited toxicity
in cell‐based assays (IC50 ≥ 200μM)
34 making such tellurophenes ideal
probes for mass cytometry. Correspondingly, β‐2‐tellurienyl‐L‐alanine
was synthesized knowing that the related sulfur‐ and selenium‐
containing phenylalanine mimics are efficiently incorporated into pro-
teins because of the tolerance of the phenylalanine‐tRNA synthetase.9
The telluro‐phenylalanine analogue was found to behave as an
excellent phenylalanine isostere since it is incorporated into proteins
via the native translation machinery without phenylalanine starvation
in vitro and in vivo allowing its measurements by mass cytometry
techniques. It looks also as a promising probe in X‐ray crystallography
as the electron density of tellurium is known to generate isomorphous
and anomalous difference Patterson maps. In this context, its proper-
ties should be superior to those of telluromethionine that suffers from
a more facile oxidation when exposed on the protein surface (see Sec-
tion 2.1) but with the drawback of a generally higher number of Phe
residues in proteins compared with Met.5 | SERINE AND CYSTEINE CHALCOGEN
ANALOGUES
In the serine/cysteine series, also selenocysteine is a proteinogenic
amino acid that is inserted into proteins by a special translation mech-
anism,35,36 while the tellurocysteine is again only tolerated by the
cysteinyl‐tRNA synthetase.11
In this series of chalcogen amino acids, the related hydroxyl, thiol,
and selenol side chain groups of serine (pKa 13), cysteine (pKa 8.25),
and selenocysteine (pKa 5.24‐5.63) differ significantly in the nucleo-
philicity leading to different structural and functional properties.37-39
While the cysteine residues form the known important structural
disulfide crosslinks for stabilization of tertiary structures in peptides
and proteins,40,41 the peroxides of serine would be biologically too
dangerous because of their oxidation power. Although serine and cys-
teine differ considerably in the nucleophilicity, both residues play a
central role in proteases. In the catalytic triad of serine proteases, an
aspartyl residue is required to increase via hydrogen bonding thenucleophilicity of the serine hydroxyl group, while such a helping res-
idue is not required in the cysteine proteases.
Besides the established role of disulfides crosslinks in cysteine‐
rich peptides and proteins for stabilizing related tertiary structures,
vicinal disulfides in specific sequence motifs such as the Cys‐Xaa‐
Yaa‐Cys act as highly efficient active sites of thiol‐protein oxidore-
ductases.42,43 This active‐site motif of thioredoxins and
glutaredoxins is involved in the reduction of intermolecular and
intramolecular disulfide bonds and other forms of oxidized cysteines,
and in protein disulfide isomerases, this bis‐cysteinyl motif catalyzes
the oxidative folding of secretory proteins into their native struc-
tures.44 This has, therefore, been called a “rheostat at the active
center.” Indeed, changes of the residues that separate the two cyste-
ines affect the redox potentials, thus structuring the proteins for a
particular redox function.45,46 Besides the effect of the dipeptide
intervening sequence,47 which is also well supported by the redox
potentials of synthetic fragments related to their active sites48 (
Table 1), the redox properties of these active sites are strongly
governed by the conformational restrictions imparted by the overall
almost identical thioredoxin‐like structure of the oxidoreduc-
tases.42,47 These structural effects were further evidenced by the
redox potentials of conformationally restricted cyclic active‐site
(bis‐cysteinyl)hexapeptides related to oxidoreductases,56 when com-
pared with those of the linear unconstrained peptides (Table 1).5.1 | Selenocysteine as isosteric replacement of
cysteine
Selenium and sulfur possess very similar atomic sizes, bond lengths to
carbon, homodimeric bond lengths, and electronegativity. Correspond-
ingly, selenocysteine represents an isosteric analogue of cyste-
ine.3,4,57,58 This was already demonstrated with early synthetic
selenocysteine/selenocystine analogues of bioactive peptides such as
oxytocin, somatostatin, and rat α‐natriuretic peptide, which retained
the bioactivities of the parent Cys‐peptides.58 The isosteric character
was then fully confirmed by comparing the NMR structures of
[Sec3,11,Nle7]‐endothelin,59 [Sec7]‐ and [Sec34]‐IL‐8,60 [Sec1,11]‐
apamin,61 and Sec‐analogues of the α‐conotoxins ImI62 andAuIB63with
those of the parent Cys‐peptides but even more accurately by the
superposition of the X‐ray structures of α‐PnIA and α‐[Sec3,16,Leu10]‐
PnIA63 and X‐ray diffraction analysis of selenocysteine‐mutant
proteins.64,655.2 | Synthesis of selenocysteine/selenocystine
peptides and proteins
The most efficient strategies for the synthesis of
selenocysteine/selenocystine peptides have been comprehensively
reviewed.4,57,66 From the large experimental work performed so far,
mainly two synthetic strategies have emerged on the basis of the
Fmoc/tBu and Boc/Bzl protection schemes, respectively.
TABLE 1 Apparent redox potentials (E′0, mV) of thiol/disulfide oxidoreductases, their linear active‐site fragments, and related cyclic
hexapeptides as extracted by the Nernst equation from the equilibrium constants of exchange reactions with the reference redox systems
Enzyme/Active‐Site Fragment E′0 Ref
Thioredoxin (Trx) −270 49
Ac‐Trp‐Cys‐Gly‐Pro‐Cys‐Lys‐His‐Ile‐NH2 [His
37]‐trx‐32-38 −190 48a
c[Trp‐Cys‐Gly‐Pro‐Cys‐Lys] c[Trx‐31‐36] −152 49b
Glutaredoxin‐1 (Grx1) −233 50
Ac‐Gly‐Cys‐Pro‐Tyr‐Cys‐Val‐Arg‐Ala‐NH2 Grx1‐
10-17 −215 48a
c[Gly‐Cys‐Pro‐Tyr‐Cys‐Val] c[Grx1‐10‐15] −178 49b
Protein disulfide isomerase (PDI) −110/145 51/52
Ac‐Trp‐Cys‐Gly‐His‐Cys‐Lys‐Ala‐Leu‐NH2 PDI‐
35-45 −205 48a
c[Trp‐Cys‐Gly‐His‐Cys‐Lys]> c[PDI‐35‐40] −130 49b
Thioredoxin reductase (Trr) −254/271 53
Ac‐Ala‐Cys‐Ala‐Thr‐Cys‐Asp‐Gly‐Phe‐NH2 Trr‐[134‐141] −210 48
a
c[Ala‐Cys‐Ala‐Thr‐Cys‐Asp] c[Trr‐134‐139] −204 49b
aGSH/GSSG (E′0 = −240).
54
bCysteine/cystine (E′0 = −223).
55
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methoxybenzyl (Mob) group that is removed by treatment with TFA
containing 10% DMSO yielding directly the oxidized selenocystine
peptides.67,68 Alternatively, the Sec (Mob) is deprotected with TFA
containing thioanisole and 2,2′‐dithiobis(5‐nitropyridine) (DTNP) lead-
ing to the adduct of Sec with thio‐5‐nitropyridine. The Sec(5‐Npys)
adduct can be cleaved by thiolysis,69 but it can also be reduced with
ascorbate.70 An even more gentle and facile method for deprotection
of Sec (Mob) was recently proposed and is based on the reductive
cleavage of the protecting group with a combination of TFA/TIS/
thioanisole (96:2:2) that provides complete removal yielding the pep-
tide mainly in the diselenide form.71
With the Boc strategy where the selenol function is protected by
the methylbenzyl group, the facile deselenization of the Sec (Mob) in
the iterative piperidine‐mediated Fmoc‐deprotection steps is
avoided.68 Moreover, the facile racemization of Sec residues can read-
ily be suppressed by the in situ neutralization protocol of solid‐phase
peptide synthesis.66 The final HF deprotection step at 0°C for all
protecting groups leads to the Sec residues already oxidized to the
expected diselenide or mixed selenosulfide bonds even under the very
strong acid conditions.63,72
Alternatively, a cost‐efficient approach can be applied for the syn-
thesis of short selenocystine peptides by reacting the related
β‐chloroalanyl‐peptides with Na2Se2
73 in protic solvents such as
methanol avoiding by this way protection and deprotection of the
selenocysteine residues.74
Using prokaryotes incorporation of selenocysteine into recombi-
nant natural Sec‐proteins is rather inefficient75 and requires the Sec‐
expression machinery.76 Therefore, recombinant expression of natural
and designed seleno‐proteins is not yet a routinely applied method for
the production of seleno‐peptides and ‐proteins.77 Conversely, recom-
binant expression of selenocysteine variants of Cys‐containing
proteins in Cys‐auxotrophic E coli was found to proceed moresuccessful as exemplarily shown for (Se)2‐thioredoxin
78 and subse-
quently also for various other Sec‐mutants of proteins.
However, a very efficient alternative to this recombinant technol-
ogy proved to be the synthetic approach to natural Sec‐proteins or
Sec‐mutants of Cys‐proteins as comprehensively reviewed more
recently.77,79 This synthetic strategy relies mainly on the assembly of
suitable fragments by the native chemical ligation (NCL) and expressed
protein ligation (EPL) where because of the similar nucleophilic prop-
erties of Sec to those of Cys, the reaction of N‐Sec‐peptide segments
with synthetic or expressed peptide thioester is exploited to produce
seleno‐proteins.80-835.3 | Redox potential of selenocysteine
While the highly isomorphous character of disulfides and diselenides is
perfectly suited for atomic mutants in X‐ray crystallography, the sele-
nium and sulfur chemistry diverges most prominently in the redox
properties.
Using cyclic voltammography with a dropping mercury working
electrode, a redox potential of selenocystine of E′0 = −488 mV vs
NHE was determined.84 This very negative value differs significantly
from that of selenocysteamine (E′0 = −352/−368 mV)
85,86 deter-
mined by exchange reaction with DTT (E′0 = −323/327 mV).
87,88
This difference may likely derive from absorption of the selenol on
the dropping mercury electrode. Therefore, alternatively, the redox
potentials of diselenide and mixed selenide/sulfide were determined
for the Sec11,14‐ and Sec11,Cys14‐Grx1‐10-17 octapeptides related to
the active site of glutaredoxin‐1 (Grx1) (Table 2).92 This choice was
based on the observation that this short active‐site fragment shows
only minimal effects imparted by the 3D fold of the protein on the
apparent redox potential of the bis (cysteinyl)‐octapeptide Cys11,14‐
Grx1‐10-17 (E′0 = −215 mV).
48 Moreover, it was only minimally
TABLE 2 Redox potentials of disulfide‐, diselenide‐, and selenosulfide amino acids, peptide, and proteins
Compounds Reference Redox System E′0, mV, (Ref)
GSH/GSSG Lipoamide (−288 mV) −24054
GSeH/GSeSeG DTT (−327 mV) −40789
Arg‐vasopressin GSH/GSSG (−262 mV) −22890
Oxytocin GSH/GSSG (−262 mV) −21690
Somatostatin GSH/GSSG (−262 mV) −22891
Glutaredoxin‐1 (Grx1) Trx (−270 mV) −23350
Ac‐Gly‐Cys‐Pro‐Tyr‐Cys‐Val‐Arg‐Ala‐NH2 Grx1‐
10-17 GSH/GSSG (−240 mV) −21548
Ac‐Gly‐Sec‐Pro‐Tyr‐Sec‐Val‐Arg‐Ala‐NH2 Sec
11,Sec14‐Grx1‐10-17 DTT (−323 mV) −38186
Ac‐Gly‐Sec‐Pro‐Tyr‐Cys‐Val‐Arg‐Ala‐NH2 Sec
11,Cys14‐Grx1‐10-17 DTT (−323 mV) −32692
Glutaredoxin‐3 (Grx3) Trx (−270 mV) −19850
[Sec11,Cys14]‐Grx3 Trx (−270 mV) −26072
[Cys11,Sec14]‐Grx3 Trx (−270 mV) −27572
[Sec11,Sec14]‐Grx3 Trx (−270 mV) −30972
Cys/Cys2 GSH/GSSG (−240 mV) −223
93
Sec/Sec2 DTT (−332 mV) −386
94
MORODER AND MUSIOL 7 of 15affected by the neighbouring amino acid residues compared with the
redox potential of cysteine as amino acid (E′0 = −223 mV).
93 It also
was found to be similar to the values previously determined for
other unconstrained linear bis (cysteinyl)‐peptides such as Arg‐
vasopressin and oxytocin90 as well as somatostatin.91
As shown in Table 2, the redox potential of the bis
(selenocysteinyl)‐peptide (E′0 = −381 mV)
92 was found to be remark-
ably lower than that of DTT (E′0 = −323/327 mV)
87,88 but very similar
to the electrode potential of selenocysteine determined by using a
graphite electrode (E′0 = −386 mV).
94 Conversely, the redox potential
of the mixed Sec,Cys‐peptide (E′0 = −326 mV) was similar to that of
DTT but still significantly more reducing than that of the parent bis
(cysteinyl)‐peptide.
By comparing the redox potentials of the bis (cysteinyl)‐peptides
related to the active sites of various thiol‐protein oxidoreductases, sig-
nificant effects of the structural constraints of the intact enzymes
were clearly observed. Very similar structural effects were imparted
even on the redox potentials of the diselenide and sulfenylselenide
groups in the Sec‐analogues of Grx3 (Table 2).72
5.4 | Synthesis of cysteine‐rich peptides by the
selenocysteine strategy
The strong differences of more than 100 mV between the redox
potentials of disulfides and diselenides and to lesser extents between
disulfides and selenosulfide groups make formation of a diselenide and
even mixed selenosulfide highly favored over that of a disulfide bond.
It was known that oxidative folding of cystine‐rich peptides already
with two disulfide bonds rarely produces quantitatively the native
disulfide isomer like in apamin95 but more often mixtures of the native
disulfide isomer contaminated at differing extents by the nonnative
isomer like in endothelin‐1.96The ability of selenocysteine to act as an internal “chaperone” and
thus to dictate the folding pathway of cysteine‐rich peptides was first
confirmed by the synthesis of seleno‐endothelin‐1.59 Indeed, air oxi-
dation of its fully reduced Sec3,11,Cys1,15,Nle7‐analogue produced
quantitatively the native diselenide3‐11,disulfide1‐15 ribbon isomer.
Conversely, in the case of apamin, not only the tetrathiol‐precursor
folds quantitatively into the native [Cys1‐11,Cys3‐15]‐globule struc-
ture95 but even the nonnative [Cys1‐15,Cys3‐11]‐ribbon and [Cys1‐3,
Cys11‐15]‐beads isomer, prepared as des‐(16‐18)‐apamin analogues
by regioselective disulfide pairing procedures, were shown to convert
quantitatively into the native fold when equilibrated in the GSH/GSSG
(15.0/2.3mM) redox buffer at pH 7.4.97 As expected from the redox
potential of the selenocysteine, air oxidation of the fully reduced
[Sec1‐11,Cys3‐15]‐, [Cys1‐15, Sec3‐11]‐, and [Sec1‐3, Cys11‐15]‐apamin
analogues was found to generate exclusively the wt and the two non-
native ribbon and beads diselenide/disulfide isomers, respectively (
Figure 7).98
Despite the different disulfide/diselenide crossbridging in the
three isomers, the NMR derived structures revealed a surprising per-
sistence of the main structural elements: These are the C‐terminal α‐
helix and the N‐terminal β‐bend as shown in Figure 7.61 This would
suggest a rather low difference in free energy of folding of the three
isomers (for the native isomer, a value of −4.5 kcal/mol at pH 7.0
and 20°C was reported99) and thus also explain why equilibration of
the two nonnative diselenide‐quenched isomers with GSH/GSSG mix-
tures at different ratios under exclusion of air did not result in a
reshuffling even at minor extents into the native isomer with genera-
tion of mixed selenosulfide bonds. Because of this modest stability of
apamin in its native fold, the intrinsically higher stability of a nonnative
diselenide bond is sufficient to offset the preferential conformational
stabilization of the native crossbridging, thus allowing formation of
the nonnative isomers. This, however, may not be the case in peptides
FIGURE 7 Solution structure of [Sec1‐11,Cys3‐15]‐apamin (wt globular fold), [Cys1‐15,Sec3‐11]‐apamin (ribbon isomer), and [Sec1‐3,Cys11‐15]‐
apamin (beads isomer) as determined by NMR61
FIGURE 8 Anaerobic oxidation of linear diselenide [Sec5‐Sec14)‐
BPTI with the four residual Cys residues as free thiols with a fivefold
excess of GSSG leads to the native intramolecular [Cys30‐Cys51]‐
disulfide (yellow) and the two [Sec5‐Cys55]‐ and [Sec14‐Cys38]‐
selenosulfide bonds (pink‐yellow) in the native tertiary structure and in
more than 70% yield after 30 h.101,102 A similar behavior was
observed at neutral pH; air oxidation in the absence of GSSG leads to
70% to 80% seleno‐BPTI, while native reduced BPTI folds extremely
slowly and inefficiently (12% after 28 h) under such conditions
8 of 15 MORODER AND MUSIOLand proteins where structural disulfides can be exceptionally stable
with redox potentials ranging from −350 to −470 mV,100 thus compet-
ing or even offsetting that of a diselenide as in the case of bovine
pancreatic trypsin inhibitor (BPTI) with a nonnative diselenide bridge
(vide infra).101,102
This latter problem should not be encountered when diselenides
are used to replace native disulfides. In such cases, even the redox
potential of the diselenide should become more negative and, corre-
spondingly, further stabilize the native side chain bridging framework
even in reducing environments such as GSH/GSSG. Indeed, this was
fully confirmed by the very high yields of correct folds obtained in a
large series of conotoxins with two disulfide bonds by replacing one
with a diselenide.62,63
The selenocysteine approach proved to be of great help also in the
synthesis of cysteine‐rich peptides containing more than two disulfide
groups such as the inhibitory cystine knot (ICK) with one disulfide
threaded through the other two. This structural motif is found in large
classes of peptides from various natural sources including conus
peptide families. Among these toxins, the μO‐conotoxin MrVIB was
considered unfoldable. But applying the selenocysteine strategy, the
folding of the related [Sec9‐25]‐, [Sec2‐20]‐, and [Sec19‐30]‐MrVIB
diselenide precursors was found to generate the correctly folded
Sec‐analogues in rather high yields of 61%, 42%, and 47%, respec-
tively.103 Since enhanced kinetics of disulfide formation was observed
in selenopeptides, the rate increase has been in first instance attrib-
uted to conformational effects. However, diselenides as additives
were known to efficiently catalyze oxidative protein folding.104,105
Correspondingly, the kinetics of oxidative folding of the μ‐conotoxin
SIIIA and ω‐conotoxin GVIA, both containing the cystine knot ICK,
were compared with the kinetics of formation of the correctly folded
[Sec4‐19]‐SIIIA and [Sec8‐19]‐GVIA. The results clearly revealed an effi-
cient catalytic effect of even intramolecular diselenides in the forma-
tion of the correct disulfides.106
This can be explained by the fact that the diselenide bond is
weaker than the corresponding disulfide bond and thus is easier to
break and to be cleaved by thiols. The way that selenium accelerates
in the case of a thiol/diselenide exchange reaction is that the electro-
philic selenium atom being attacked is a much better electrophile than
sulfur and accelerates the reaction rate 100‐fold more in comparison
with sulfur.107 Correspondingly, diselenides can catalyze thiol‐disulfide exchange reactions required to reach the thermodynamic
most favored framework.101,102
Another interesting application was reported by Metanis and
Hilvert who used a nonnative diselenide to catalyze the correct oxida-
tive folding of BPTI.101,102 Very intensive studies on the oxidative
folding pathway of BPTI had disclosed the formation of a significant
amount of a kinetically trapped intermediate (N*) containing the two
native disulfide bonds [Cys5‐Cys55] and [Cys14‐Cys38].108 As men-
tioned above, because of the higher polarizability of selenium than
of sulfur, even nonnative diselenides could catalyze correct folding if
sufficient conformational energy is available to neutralize the thermo-
dynamic benefit of a diselenide bond. With this hypothesis in mind,
two selenocysteines were placed in the positions 5 and 14 of BPTI
to induce in first instance formation of the nonnative Sec5‐Sec14
diselenide bond, which then was found to undergo thiol diselenide
exchange reactions bypassing the kinetic trapped intermediate N*
and generating in high yields correctly folded BPTI with two
MORODER AND MUSIOL 9 of 15selenosulfide bridges [Sec5‐Cys55] and [Sec14‐Cys38] in addition to the
disulfide [Cys30‐Cys51] (Figure 8).101,102
This surprising strong effect of intramolecular catalysis of
diselenide groups on the folding of cysteine‐rich peptides was compel-
ling to apply the selenocysteine strategy in the attempt to advance in
the still existing problem of efficient insulin syntheses as recently
reviewed.109 Indeed, acceptable yields in the correct assembly of the
A‐ and B‐chain into native insulin with the intramolecular A6‐A11 and
the two intermolecular A7‐B7 and A20‐B19 disulfides could mainly be
achieved applying the most advanced regioselective Cys‐protection
schemes to guarantee in optimal yields the correct native disulfide
pairing. While these synthetic approaches imply extensive experimen-
tal work, the direct oxidative assembly of the A‐ and B‐chain failed in
terms of yields unless very optimized conditions (A‐chain: B‐chain 2:1;
GSSG/GSH and catalytic amounts of PDI) were applied.110 Alterna-
tively, yields similar to those of the oxidative folding of native proinsu-
lin (70%‐80%) could be achieved with various biomimetic single‐chain
proinsulin constructs in which the natural 35‐residue C‐peptide that
connects the C‐terminus of the B‐chain with the N‐terminus of the
A‐chain was replaced by peptidic and even nonpeptidic tethers of
varying sizes and chemical structure. Among these artificial single‐
chain insulin precursors, the most appealing in terms of atom economy
was the “Ester‐Insulin” of Kent and associates in which theFIGURE 10 Possible placement of the two
selenocysteines in synthetic linear A‐ and B‐
chains for induction of diselenide‐
crossbridged heterodimeric insulin‐folding
precursors
FIGURE 9 Conversion of ester‐insulin to LysB28,ProB29‐insulin
variant via oxidative folding and saponification according to Kent
and associates111,112crosslinking of the A‐ and B‐chain is achieved by esterification of the
β‐hydroxyl group of ThrB30 with the γ‐carboxyl group of GluA4 yield-
ing an insulin precursor of a foldability similar to that of natural proin-
sulin; a simple saponification of the ester group produces the insulin in
correctly folded structure and yields similar to those obtained with
optimized single‐chain proinsulins (Figure 9).111-113
This experimental evidence clearly confirms that a simple
crosslinking of the A‐ and B‐chain to the heterodimer via an ester link-
age would suffice for reducing the entropic penalty in the oxidative
folding of the two chains in a manner similar to the proinsulin precur-
sor. These findings were strongly suggesting an application of the
selenocystine strategy to produce an A7‐B7 or A20‐B19 diselenide
as interchain crosslink with similar atom economy as the ester‐insulin
but with the advantage of the intramolecular folding catalysis by the
diselenide (Figure 10).
With this working hypothesis in mind and knowing about the facile
deselenization of the protected Sec (Mob) residues during the multi-
step synthesis of larger peptide chains with the Fmoc/tBu strategy,68
the laboratories of Hojo and Iwaoka combined their efforts in the syn-
thesis of the A‐ and B‐chains containing the Sec (Mob) residues in
position A7 and B7 of bovine insulin, respectively.114 For the required
handling of the peptides in the purification step, both the Cys and Sec
residues were kept in the cysteine(S‐pyridylsulfanyl) and selenosulfide
forms, which were then reduced with DTT (4 equivalents for the total
number of Cys and Sec residues) prior to folding in a 1:1 mixture of
the A‐ and B‐chain at 200μM concentration under thermodynamic
control by air oxygen in a buffer at pH 10 (4°C) in the presence of
0.5M urea to solubilize the A‐chain (Figure 11). The oxidative assem-
bly was monitored by high‐performance liquid chromatography
(HPLC) and was found to be finished after 24 hours yielding upon
HPLC purification 27% insulin. Slightly higher yields were obtained
with TCEP as reducing agent. Compared with the assembly of the A‐
and B‐chain under similar conditions with about 3% yield after 4 days,
the selenocysteine strategy proved to be very successful in terms of
reaction rates and yields by largely preventing the entropic penalty
in the chain crosslinking at those low micromolar concentrations.
The synthetic bovine seleno‐insulin was found to exhibit the identical
tertiary structure as the wt insulin, practically the identical bioactivities
in terms of phosphorylation levels of Akt and GSK3β in Hela cells, but
significantly increased resistance to the insulin degrading enzyme, a
very positive property for a fully active insulin analogue.114 The highly
beneficial effect of the catalysis by the intermolecular diselenide and
the significant reduction of the entropic penalty by the highly favored
interchain‐diselenide crosslink was fully confirmed.
FIGURE 12 Oxidative assembly of the human [SecA6,SecA11]‐insulin
from the two chains into the native insulin tertiary structure117-119
FIGURE 11 Oxidative assembly of the bovine [SecA7,SecB7]‐insulin
from the two chains into the native insulin tertiary structure114
10 of 15 MORODER AND MUSIOLFIGURE 13 Synthesis of [Tec1,Tec6]‐oxytocin on MBHA‐
polystyrene resin129From extensive studies on folding of insulin and proinsulin, it was
known that the intrachain disulfide CysA6‐CysA11 is important for
induction of the overall insulin structure, even if not essential.115
However, this disulfide if preferentially installed leads to conforma-
tional constraints that structurally preorganize the A‐chain facilitating
the correct formation of the remaining interchain disulfides.116 On
the basis of this information, Metanis and associates approached the
synthesis of human seleno‐insulin by placing the diselenide in the A‐
chain as intramolecular crossbridge to restrict the conformational
space of the A‐chain and thus to possibly improve a correct A‐ and
B‐chain oxidative assembly.117-119 Unexpectedly, the synthetic linear
[SecA6‐SecA11]‐A‐chain proved to be highly soluble similarly to the
sulfitolized A‐ and B‐chains and thus with no expressed tendency to
aggregation.120 This beneficial solubility property allowed its use in
the oxidative assembly reaction together with the sulfitolized B‐chain
readily prepared by oxidative sulfitolysis of commercial human insulin.
The air oxidation was performed at significantly higher concentrations
than in the preceding procedure with the SecA7‐ and SecB7‐chains. As
shown in Figure 12, upon reduction of the B‐chain sulfonate with DTT
in stoichiometric equivalents to the concentration of the sulfonate
groups, but with the SecA6‐SecA11‐A‐chain as a mixture of oxidized
products (selenylsulfides or disulfide/diselenide), the two chains at a
1:1 molar ratio and 1.2mM concentration were exposed to air oxida-
tion. After 8 hours, the product was isolated by HPLC in about 30%
yield confirming the strong catalytic effect of the intrachain diselenide
in both the recombination rates and final yields. This human seleno‐insulin variant was found to exhibit the identical tertiary structure as
the native insulin. Identical bioactivities as the wt human insulin and
resistance to both reductive and enzymatic degradation were real-
ized.117-119
Both examples of using selenocystine as catalysts in the oxidative
assembly of bovine and human seleno‐insulin from designed Sec‐
variants of the A‐ and B‐chain clearly revealed significantly increased
rates of oxidative folding and yields of the desired products with
native‐like structures and activities. These data provide new
approaches for the efficient generation of insulin analogues containing
even unnatural amino acid residues in view of developing of new‐
insulin variants with improved therapeutic values.5.5 | Tellurocysteine as isosteric replacement of
cysteine
Unlike the chalcogens oxygen, sulfur, and selenium that find biological
use, for tellurium, no biological function is known so far. However, in
rare cases, bacteria and fungi grown in the presence of sodium tellu-
rite and in the absence of sulfur were found to produce tellurium‐
containing amino acids (tellurocysteine, tellurocystine, and
telluromethionine) and to bioincorporate these into proteins,11,121 a
process that has to occur by the tolerance of the methionyl‐ and
cysteinyl‐tRNA synthetases. On the basis of experience with the accu-
mulation of selenium in proteins of Spirulina platensis, a blue‐green
TABLE 3 A comparison of bioactivities and resistance to digestion of seleno‐ and telluro‐oxytocin with the wild‐type hormone131
Oxytocin (OT) Human OT Receptor Human Serum
binding Ki (nM) functional EC50 (nM) half‐life (h)
wt‐OT 0.79 + 0.16 15.0 + 2.5 11.6 + 1.9
[Se‐Se]‐OT 11.8 + 4.1 18.0 + 12 25.3 + 5.9
[Te‐Te]‐OT 7.6 + 2.7 27.3 + 7.4 24.2 + 2.2
MORODER AND MUSIOL 11 of 15algae, in the form of selenomethionine and selenocysteine,122,123
accumulation of tellurium into the phycobiliproteins phycocyanin and
allophycocyanin of S platensis was found to proceed successfully lead-
ing to enhanced antioxidant activities of both proteins.124 These
results strongly support such novel organic tellurium species for appli-
cation in antioxidation for the treatment of diseases related to oxida-
tive stress.
On the basis of these results, even recombinant expression of
the tellurocysteine‐containing glutathione‐S‐transferase from Lucilia
cuprina (LuGST‐1) was found to occur in good yields with a Cys‐
auxotrophic expression system in the presence of synthetic
tellurocysteine,125 although tellurocysteine is apparently on the border-
line in terms of the substrate tolerance of cysteinyl‐tRNA from E coli.126
Alternatively, the Tec amino acid was inserted into subtilisin to form
semisynthetic tellurosubtilisin127,128; however, this chemical modifica-
tion has the disadvantage that it can be applied only at active‐site serine
residues like Ser221 in subtilisin. Thus, the development of a general
strategy for the incorporation of Tec into proteins so far remains a chal-
lenging task.
On the other side, the redox potential of tellurocysteine/
tellurocystine determined by cyclic voltammography usingmercury film
coated glass carbon electrode is characterized by an intrinsically lower
redox potential (−850 mV versus Ag/AgCl) than that of
selenocysteine/selenocystine (−640 mV versus Ag/AgCl) making it an
interesting mutant of Cys‐ and Sec‐containing proteins because of its
considerably more reducing properties.126
The synthesis of tellurocysteine has been reported125,129 as well as
the synthesis of (Boc‐Tec‐OH)2
130 and H‐Tec (Meb)‐OH129 as
potential intermediates for the synthesis of Tec‐peptides. However,
oxytocin as the only reported synthetic Tec‐containing peptide so
far was prepared according to the synthetic route shown in
Figure 13.129
A comparison of the oxytocin ditelluride with its wild‐type and
diselenide variant clearly revealed a visibly reduced receptor affinity
and functional property (Table 3).131 However, it was found to be
surprisingly stable in view of general observations with
organotellurium compounds where the ditelluride group was found
to be light‐sensitive with tendency to hydrolyze and to decompose
forming telluroxides, tellurite, tellurate, and even elemental tellu-
rium.132 In addition, also the carbon‐Te bond (around 200 kJ
mol−1) is less stable than the carbon‐Se bond (234 kJ mol−1) and
the carbon‐S bond (272 kJ mol−1) with the carbon‐O bond being
the most stable (358 kJ mol−1). In this context, the Te‐alkyl com-
pounds were found to be generally less stable than the Te‐aryl or
Te‐alkylaryl compounds, a fact that was confirmed in the case oftelluromethionine‐protein analogues (see Section 2.1 and Besse
et al3) in comparison with the stability of simple organotellurium
compounds.132 The higher stability of the alkylaryl tellurides could
well be exploited for the synthesis of Tec‐peptides with Tec (Mob)
or Tec (Meb) protected tellurocysteine.
The promising therapeutic properties already reported for simple
organotellurium derivatives with antimicrobial, antioxidant, immuno-
modulatory, and anticancer activities should foster intense research
also with small purposely designed Tec‐containing low‐mass peptides
and related derivatives.6 | CONCLUSION AND REMARKS
As among the members of the chalcogen elements, oxygen, sulfur, and
selenium play vital roles in the chemistry of life, the apparent lack of
any biochemical function for tellurium is rather surprising also in view
of its properties that are similar to that of sulfur and selenium. While
oxygen is essential for life on Earth, sulfur exerts crucial roles in cellu-
lar processes, biocatalysis, and protein structures. This may well be the
reason why great attention was paid to study and exploit the
biochemistry and properties of sulfur as well as more recently of
selenium, the latter because of its two faces as it is both toxic to all
organisms, but also essential to many bacteria and animal spe-
cies.133,134 Thereby, the redox chemistry was found to represent the
largest difference between the two chalcogens, a fact that has been
exploited in nature to enhance and adjust redox properties of
selenium‐containing enzymes and proteins, but also in the laboratory
to direct oxidative folding of cysteine‐rich peptides and enhance their
thermodynamic stability in view of potential therapeutic applications
(see Section 5). On the basis of the superb results obtained by replac-
ing sulfur with selenium particularly in methionine, but also in cysteine
for producing heavy atom analogues with considerable advantages in
protein and peptide X‐ray crystallography, a similar approach has been
proposed also for bioincorporation of telluromethionine (see Section
2.1). This approach has not found the due attention particularly
because of the facile oxidation and decomposition of the
telluromethionine. Such drawback can, however, be overcome by
using the Te‐containing phenylalanine and tryptophan analogues.
Indeed, on the basis of optimized synthesis of β‐selenolo[3‐2b]
pyrrolyl‐L‐alanine and β‐selenolo[2‐3b]pyrrolyl‐L‐alanine compared
with the previously known methods (see Section 3 and Phillips et al5
and Welch and Phillips6) to generate enzymatically [4,5]Se‐Trp and
[6,7]Se‐Trp for their incorporation into dihydropholate reduc-
tase,135,136 the synthesis of 6H‐telluro[2‐3b]pyrrolo for its enzymatic
12 of 15 MORODER AND MUSIOLconversion to the Te‐Trp analogue has been reported.137 Such a
tellurium‐containing Trp analogue as well as the β‐2‐tellurienyl‐L‐ala-
nine as Phe analogue9 where in both cases the tellurium is incorpo-
rated into the aromatic ring system should be significantly more
stable to oxidation and decomposition than the alky‐Te‐alkyl com-
pounds like telluromethionine.34,130 This observation may well help
raising the pharmacological perspective of tellurium compounds even
at the level of peptides and proteins from a forgotten to an emerging
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